Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance

Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance

US Patent 11419871 · Granted Aug 23, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Oxadiazoline compound or salts thereof, agricultural and horticultural fungicide2025
Oxadiazole compounds or salts thereof, agrohorticultural fungicides containing t2024
Fusions and method for detecting same2024
Fusions and method for detecting same2024
Oxadiazoline compounds or salts thereof, agrohorticultural fungicides containing2024
Primary culture method2023
Anti-podoplanin antibody2022
Oxadiazole compound or salts thereof, agricultural/horticultural fungicide conta2021
Fusions and method for detecting same2021
Fusions and method for detecting same2021
Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance2020
Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance2020